3SBio Income Statement | StatInvestor

Health Care & Life Sciences » Biotechnology | 3SBio Inc.

3SBio Inc. | Income Statement

Fiscal year is January-December. All values HKD Millions.

2013

2014

2015

2016

2017

2018

Sales/Revenue

1,105

1,423

2,064

3,268

4,306

5,429

Cost of Goods Sold (COGS) incl. D&A

115

119

291

448

780

1,039

Gross Income

989

1,305

1,773

2,820

3,526

4,390

SG&A Expense

747

870

1,230

1,820

2,214

2,879

EBIT

242

443

555

1,001

1,312

1,511

Unusual Expense

127

227

Non Operating Income/Expense

149

130

Interest Expense

173

163

164

Pretax Income

269

455

720

1,007

1,287

1,781

Income Tax

142

159

205

259

Equity in Affiliates

Consolidated Net Income

121

367

649

835

1,066

1,513

Net Income

121

367

649

833

1,079

1,513

Net Income After Extraordinaries

121

367

649

833

1,079

1,513

Net Income Available to Common

121

367

649

833

1,079

1,513

EPS (Basic)

0.05

0.15

0.28

0.33

0.43

0.60

Basic Shares Outstanding

2,424

2,255

2,524

2,535

2,541

EPS (Diluted)

0.05

0.15

0.28

0.32

0.42

0.58

Diluted Shares Outstanding

2,424

2,299

2,563

2,654

2,754

EBITDA

293

484

643

1,170

1,597

1,885

Other Operating Expense

Non-Operating Interest Income

Minority Interest Expense

About 3SBio

View Profile

Address	Shenyang Economy & Tech Development Shenyang Liaoning 110027 China
Employees	-
Website	http://www.3sbio.com
Updated	07/08/2019
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.